Pfizer CEO Albert Bourla said launch products are growing 32% this quarter and already amount to roughly $15-16 billion annualized revenue. He also said Pfizer beat analyst EPS expectations 11 times out of 11 over the last 11 quarters, and that the company expects high single-digit growth over the next five years.
PFE · Pfizer Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Pfizer named Cecile Guegan Chief Financial Officer effective November 1, 2026, following her interim role since August 16, 2026, with a $1,300,000 base salary and $1,300,000 annual target cash incentive.
Pfizer reported third-quarter 2026 revenue of $16.6 billion, non-COVID operational growth of 7%, and raised full-year 2026 revenue guidance by $1.5 billion at the midpoint and adjusted diluted EPS guidance to $2.95-$3.05.
Pfizer Inc reported revenue of $46.1 billion, up 2%, while pretax income from continuing operations fell $3.3 billion to $5.9 billion. Expected cost realignment and manufacturing optimization savings rose to $6.7 billion and $3.0 billion through 2029.
Pfizer Inc. reported third-quarter 2026 revenues of $16.6 billion, flat operationally year over year, and raised full-year 2026 revenue guidance to $62.0 to $64.0 billion and Adjusted diluted EPS guidance to $2.95 to $3.05.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. Pfizer raised 2026 revenue and adjusted diluted EPS guidance as launched and acquired products grew 32% operationally, non-COVID revenue grew 7%, cost savings supported margins, and Elrexfio and Tilrekimig advanced positive late-stage programs. Total revenue was relatively flat, reported earnings declined, COVID-19 and Prevnar revenues fell, R&D spending increased, and generic, biosimilar and loss-of-exclusivity competition remained a headwind.
- + Pfizer raised full-year 2026 revenue guidance by $1.5 billion at the midpoint and raised and narrowed adjusted diluted EPS guidance.
- + Launched and acquired products grew 32% operationally in the third quarter. new
- + Non-COVID product revenue grew 7% operationally in the third quarter. new
- + Elrexfio met the primary endpoint of a Phase 3 multiple myeloma study and reduced the risk of disease progression or death. new
- + Tilrekimig met its primary Phase 2 endpoint in atopic dermatitis and entered a pivotal Phase 3 program. new
- − A one-time $650 million Innovent-related acquired IPR&D charge reduced adjusted diluted EPS by approximately $0.10. new
- − Full-year guidance anticipates a $1.1 billion revenue headwind from generic and biosimilar competition, while the 2027 outlook includes loss-of-exclusivity pressure. new
- − COVID-19 product and Prevnar family revenues declined operationally in the third quarter. new
- − Pfizer completed no share repurchases in 2026 through November 3 and did not anticipate any in its current 2026 guidance. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Abrysvo Global Revenues | $208M | the three months ended June 28, 2026 filing | — |
| Adjusted diluted EPS non-GAAP | $1.52 | Six Months Ended June 28, 2026 | — |
| Adjusted R&D Expenses non-GAAP | $2.73B | Second-Quarter 2026 | — |
| Comirnaty Global Revenues | $261M | the three months ended June 28, 2026 filing | — |
| Effective tax rate for non-GAAP Adjusted income non-GAAP | 15.5% | six months ended June 28, 2026 | — |
| Eliquis Global Revenues | $2.43B | the three months ended June 28, 2026 filing | — |
| Eliquis revenue growth (operational, global) | 19% | Second-Quarter 2026 | — |
| Ibrance Global Revenues | $1.06B | the three months ended June 28, 2026 filing | — |
| Lorbrena Global Revenues | $354M | the three months ended June 28, 2026 filing | — |
| Lorbrena revenue growth (operational, global) | 37% | Second-Quarter 2026 | — |
| Non-GAAP Adjusted cost of sales non-GAAP | $7.06B | Six Months Ended June 28, 2026 | — |
| Non-GAAP Adjusted income non-GAAP | $8.73B | Six Months Ended June 28, 2026 | — |
| Non-GAAP Adjusted net income attributable to Pfizer Inc. common shareholders non-GAAP | $4.44B | the three months ended June 28, 2026 filing | — |
| Non-GAAP Adjusted other (income)/deductions—net non-GAAP | $496M | Six Months Ended June 28, 2026 | — |
| Non-GAAP Adjusted selling, informational and administrative expenses non-GAAP | $6.26B | Six Months Ended June 28, 2026 | — |
| Nurtec ODT/Vydura Global Revenues | $421M | the three months ended June 28, 2026 filing | — |
| Padcev Global Revenues | $667M | the three months ended June 28, 2026 filing | — |
| Padcev revenue growth (operational, global) | 23% | Second-Quarter 2026 | — |
| Paxlovid Global Revenues | $21M | the three months ended June 28, 2026 filing | — |
| Prevnar family Global Revenues | $1.34B | the three months ended June 28, 2026 filing | — |
| Revenues of Launched and Acquired Products growth (operational) | 18% | Second-Quarter 2026 | — |
| Total revenues excluding contributions from Comirnaty and Paxlovid (operational growth) | 5% | the second quarter of 2026 filing | — |
| Total revenues operational increase (growth excluding foreign exchange) | 1% | the second quarter of 2026 filing | — |
| Vyndaqel family Global Revenues | $1.76B | the three months ended June 28, 2026 filing | — |
| Vyndaqel family revenue growth (operational, global) | 8% | Second-Quarter 2026 | — |
| Xtandi Global Revenues | $534M | the three months ended June 28, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PFE
this stock
Pfizer Inc
|
$156.97B | +10.6% | -1.6% | 39.3 | 2.4% |
|
LLY
ELI LILLY & Co
|
$1.27T | +25.7% | +44.7% | 43.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$643.09B | +29.1% | +6.0% | 40.6 | 0.7% |
|
ABBV
AbbVie Inc.
|
$501.19B | +24.1% | +8.6% | 48.8 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$327.41B | +26.2% | +1.3% | 136.9 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 21
Pfizer CEO Albert Bourla said launch products are growing 32% this quarter and already amount to roughly $15-16 billion annualized revenue. He also said Pfizer beat analyst EPS expectations 11 times out of 11 over the last 11 quarters, and that the company expects high single-digit growth over the next five years.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PFE | -4.5% | -9.5% | +7.5% | -9.8% | +10.6% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +1.0% | -3.2% | +13.1% | -4.5% | +5.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.